Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Lane, AA; Sweet, KL; Wang, ES; Donnellan, WB; Walter, RB; Stein, AS; Rizzieri, DA; Carraway, HE; Mantzaris, I; Prebet, T; Maris, MB; Faderl, S; Bixby, DL; Chen, J; Lindsay, R; Shemesh, S; Brooks, CL; Stone, RM; Kantarjian, HM; Jabbour, EJ; Konopleva, M

Published Date

  • December 2, 2016

Published In

Volume / Issue

  • 128 / 22

Published By


  • 6

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Conference Location

  • San Diego, CA

Conference Start Date

  • December 3, 2016

Conference End Date

  • December 6, 2016